274 related articles for article (PubMed ID: 21135251)
21. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study.
Zhen DB; Rabe KG; Gallinger S; Syngal S; Schwartz AG; Goggins MG; Hruban RH; Cote ML; McWilliams RR; Roberts NJ; Cannon-Albright LA; Li D; Moyes K; Wenstrup RJ; Hartman AR; Seminara D; Klein AP; Petersen GM
Genet Med; 2015 Jul; 17(7):569-77. PubMed ID: 25356972
[TBL] [Abstract][Full Text] [Related]
22. Interaction with PALB2 Is Essential for Maintenance of Genomic Integrity by BRCA2.
Hartford SA; Chittela R; Ding X; Vyas A; Martin B; Burkett S; Haines DC; Southon E; Tessarollo L; Sharan SK
PLoS Genet; 2016 Aug; 12(8):e1006236. PubMed ID: 27490902
[TBL] [Abstract][Full Text] [Related]
23. Pancreatic cancer heterogeneity and response to Mek inhibition.
Pedersen K; Bilal F; Bernadó Morales C; Salcedo MT; Macarulla T; Massó-Vallés D; Mohan V; Vivancos A; Carreras MJ; Serres X; Abu-Suboh M; Balsells J; Allende E; Sagi I; Soucek L; Tabernero J; Arribas J
Oncogene; 2017 Oct; 36(40):5639-5647. PubMed ID: 28581516
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer.
Tischkowitz MD; Sabbaghian N; Hamel N; Borgida A; Rosner C; Taherian N; Srivastava A; Holter S; Rothenmund H; Ghadirian P; Foulkes WD; Gallinger S
Gastroenterology; 2009 Sep; 137(3):1183-6. PubMed ID: 19635604
[No Abstract] [Full Text] [Related]
25. Functional variant analyses (FVAs) predict pathogenicity in the BRCA1 DNA double-strand break repair pathway.
Loke J; Pearlman A; Upadhyay K; Tesfa L; Shao Y; Ostrer H
Hum Mol Genet; 2015 Jun; 24(11):3030-7. PubMed ID: 25652403
[TBL] [Abstract][Full Text] [Related]
26. Plasticity of BRCA2 function in homologous recombination: genetic interactions of the PALB2 and DNA binding domains.
Siaud N; Barbera MA; Egashira A; Lam I; Christ N; Schlacher K; Xia B; Jasin M
PLoS Genet; 2011 Dec; 7(12):e1002409. PubMed ID: 22194698
[TBL] [Abstract][Full Text] [Related]
27. PALB2 links BRCA1 and BRCA2 in the DNA-damage response.
Zhang F; Ma J; Wu J; Ye L; Cai H; Xia B; Yu X
Curr Biol; 2009 Mar; 19(6):524-9. PubMed ID: 19268590
[TBL] [Abstract][Full Text] [Related]
28. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer.
Casadei S; Norquist BM; Walsh T; Stray S; Mandell JB; Lee MK; Stamatoyannopoulos JA; King MC
Cancer Res; 2011 Mar; 71(6):2222-9. PubMed ID: 21285249
[TBL] [Abstract][Full Text] [Related]
29. Context dependence of checkpoint kinase 1 as a therapeutic target for pancreatic cancers deficient in the BRCA2 tumor suppressor.
Hattori H; Skoulidis F; Russell P; Venkitaraman AR
Mol Cancer Ther; 2011 Apr; 10(4):670-8. PubMed ID: 21289082
[TBL] [Abstract][Full Text] [Related]
30. Tumor engraftment in nude mice and enrichment in stroma- related gene pathways predict poor survival and resistance to gemcitabine in patients with pancreatic cancer.
Garrido-Laguna I; Uson M; Rajeshkumar NV; Tan AC; de Oliveira E; Karikari C; Villaroel MC; Salomon A; Taylor G; Sharma R; Hruban RH; Maitra A; Laheru D; Rubio-Viqueira B; Jimeno A; Hidalgo M
Clin Cancer Res; 2011 Sep; 17(17):5793-800. PubMed ID: 21742805
[TBL] [Abstract][Full Text] [Related]
31. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Beeharry N; Banina E; Hittle J; Skobeleva N; Khazak V; Deacon S; Andrake M; Egleston BL; Peterson JR; Astsaturov I; Yen TJ
Cell Cycle; 2014; 13(14):2172-91. PubMed ID: 24955955
[TBL] [Abstract][Full Text] [Related]
32. Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.
Foo TK; Tischkowitz M; Simhadri S; Boshari T; Zayed N; Burke KA; Berman SH; Blecua P; Riaz N; Huo Y; Ding YC; Neuhausen SL; Weigelt B; Reis-Filho JS; Foulkes WD; Xia B
Oncogene; 2017 Jul; 36(29):4161-4170. PubMed ID: 28319063
[TBL] [Abstract][Full Text] [Related]
33. Routine testing for PALB2 mutations in familial pancreatic cancer families and breast cancer families with pancreatic cancer is not indicated.
Harinck F; Kluijt I; van Mil SE; Waisfisz Q; van Os TA; Aalfs CM; Wagner A; Olderode-Berends M; Sijmons RH; Kuipers EJ; Poley JW; Fockens P; Bruno MJ
Eur J Hum Genet; 2012 May; 20(5):577-9. PubMed ID: 22166947
[TBL] [Abstract][Full Text] [Related]
34. MGMT expression affects the gemcitabine resistance of pancreatic cancer cells.
Shi Y; Wang Y; Qian J; Yan X; Han Y; Yao N; Ma J
Life Sci; 2020 Oct; 259():118148. PubMed ID: 32721465
[TBL] [Abstract][Full Text] [Related]
35. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Rahman N; Seal S; Thompson D; Kelly P; Renwick A; Elliott A; Reid S; Spanova K; Barfoot R; Chagtai T; Jayatilake H; McGuffog L; Hanks S; Evans DG; Eccles D; ; Easton DF; Stratton MR
Nat Genet; 2007 Feb; 39(2):165-7. PubMed ID: 17200668
[TBL] [Abstract][Full Text] [Related]
36. PALB2 functionally connects the breast cancer susceptibility proteins BRCA1 and BRCA2.
Zhang F; Fan Q; Ren K; Andreassen PR
Mol Cancer Res; 2009 Jul; 7(7):1110-8. PubMed ID: 19584259
[TBL] [Abstract][Full Text] [Related]
37. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer.
Ono H; Basson MD; Ito H
Mol Cancer Res; 2015 Aug; 13(8):1174-84. PubMed ID: 26013168
[TBL] [Abstract][Full Text] [Related]
38. Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair.
Kausar T; Schreiber JS; Karnak D; Parsels LA; Parsels JD; Davis MA; Zhao L; Maybaum J; Lawrence TS; Morgan MA
Neoplasia; 2015 Oct; 17(10):757-66. PubMed ID: 26585231
[TBL] [Abstract][Full Text] [Related]
39. Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kuusisto KM; Bebel A; Vihinen M; Schleutker J; Sallinen SL
Breast Cancer Res; 2011 Feb; 13(1):R20. PubMed ID: 21356067
[TBL] [Abstract][Full Text] [Related]
40. Differential modulation of nicotine-induced gemcitabine resistance by GABA receptor agonists in pancreatic cancer cell xenografts and in vitro.
Banerjee J; Al-Wadei HA; Al-Wadei MH; Dagnon K; Schuller HM
BMC Cancer; 2014 Sep; 14():725. PubMed ID: 25260978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
